BCIQ Profiles

Company Profile Report

WHO prioritizing Gilead’s remdesivir, designing master protocol for 2019-nCoV outbreak

WHO plans to establish master protocol for 2019-nCoV outbreak

Gilead’s remdesivir is the most promising candidate for treating 2019-nCoV acute respiratory disease, according to a draft report of WHO’s R&D Blueprint Clinical Trials expert group.

The group agreed in principle to design a randomized, controlled master protocol that can compare multiple investigational therapies in parallel.

The report, circulated to the group on Jan. 29, states: “Among the different therapeutic options, Remdesivir was considered the most promising candidate based on the broad antiviral spectrum, the in vitro and in

Read the full 789 word article

How to gain access

Continue reading with a
two-week free trial.